Mutant IDH1 Inhibitors
1 drugsAbout Mutant IDH1
Mutant IDH1 (Isocitrate Dehydrogenase 1) is a mutated metabolic enzyme involved in the citric acid cycle. The mutation leads to the production of D-2-hydroxyglutarate (D-2HG), disrupting cellular differentiation and contributing to tumorigenesis.
Mutant IDH1 is a significant oncology target because its mutation drives tumorigenesis. Currently, there is no genetic evidence data available linking Mutant IDH1 to specific disease outcomes.
There is one FDA-approved drug, TIBSOVO (Servier), a small molecule used in oncology. TIBSOVO was first approved in 2018 and has 3 indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Myelodysplastic Syndrome with only 2 trials.
- phase3 represents biological uncertainty with 0% completion.
Top Mutant IDH1 Drugs
The competitive landscape is highly concentrated, with only Servier having an approved drug.
High market concentration suggests significant entry barriers, requiring differentiated strategies for new entrants.
Mutant IDH1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Mutant IDH1, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to diversify the therapeutic approach and gain a competitive edge.
Mutant IDH1 Clinical Trials 42 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 18 | 4 | 5 | 9 | 44% |
| Phase 2 | 19 | 2 | 0 | 17 | 100% |
| Phase 3 | 5 | 0 | 0 | 5 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Mutant IDH1 Drug Approval Timeline (2018 - 2018)
The approval timeline shows that TIBSOVO was first approved in 2018.
The recent approval and lack of subsequent approvals indicates potential for market growth but also possible saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 43 clinical trials targeting Mutant IDH1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities